|
Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children’s Oncology Group clinical trials. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Exelixis (Inst); Genentech (Inst); Genentech (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Exelixis; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer |
Research Funding - Bayer (Inst); BMS (Inst); Curis (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech; Salarius Pharmaceuticals |
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc |
|
|
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc |
|
|
No Relationships to Disclose |